Drug Interactions between lazertinib and TPOXX
This report displays the potential drug interactions for the following 2 drugs:
- lazertinib
- TPOXX (tecovirimat)
Interactions between your drugs
tecovirimat lazertinib
Applies to: TPOXX (tecovirimat) and lazertinib
MONITOR: Coadministration with weak inducers of CYP450 3A4 may reduce the plasma levels and effects of lazertinib, which is primarily metabolized by the isoenzyme. In a phase 1 study of healthy adult participants, concomitant use of the strong CYP450 3A4 inducer rifampin reduced the peak plasma concentration (Cmax) and systemic exposure (AUC) of lazertinib by 72% and 83%, respectively. Likewise, a pharmacokinetic model predicted that concomitant use with the moderate CYP450 3A4 inducer efavirenz would decrease lazertinib's steady state Cmax and AUC by at least 32% and 44%, respectively. Clinical data with less potent CYP450 3A4 inducers are not available.
MANAGEMENT: The potential for diminished pharmacologic effects of lazertinib should be considered if coadministration with a weak CYP450 3A4 inducer is clinically necessary. An alternative concomitant medication with no potential to induce CYP450 3A4 may be required.
References (2)
- (2024) "Product Information. Lazcluze (lazertinib)." Janssen Biotech, Inc.
- Janssen Research & Development, LLC (2024) A study to assess the effects of itraconazole and rifampin on lazertinib in healthy adult participants. https://clinicaltrials.gov/study/NCT04410094?tab=table
Drug and food interactions
tecovirimat food
Applies to: TPOXX (tecovirimat)
ADJUST DOSING INTERVAL: Food may increase the extent of tecovirimat absorption following oral administration. When the recommended oral dose of tecovirimat (600 mg every 12 hours) was administered with a meal (approximately 600 calories and 25 g of fat) in healthy adults weighing less than 120 kg, tecovirimat absorption increased by 39% relative to fasting.
MANAGEMENT: Oral tecovirimat should be taken within 30 minutes after a full meal containing moderate or high fat (approximately 600 calories and 25 g of fat) with 6 to 8 ounces of water.
References (1)
- "Product Information. Tpoxx (tecovirimat)." SIGA Technologies, Inc.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.